EUVIMEDEUVIMED entdecken
Crossref

Serum Paraoxonase-1: A Key Modulator of Lipid Abnormalities and Atherosclerotic Risk in Early Stage Chronic Kidney Disease

E. Keerthika, GSR Kedari, N. Ananthi

International Journal of Drug Delivery Technology · 23.05.2026 · 16 (35s)

DOI: 10.25258/ijddt.16.35s.77 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 23.05.2026. Verfasst von E. Keerthika und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) is associated with significant disturbances in lipid metabolism and increased oxidative stress, both of which contribute to the development of cardiovascular disease. High-density lipoprotein (HDL) is functionally linked to the antioxidant enzyme paraoxonase-1 (PON1), which plays a crucial role in protecting lipoproteins from oxidative modification. In CKD, PON1 activity is known to decline, thereby enhancing atherogenic risk.

Aim

To evaluate serum paraoxonase-1 (PON1) levels and examine their association with dyslipidaemia and renal function in patients with Stage 2 CKD. Materials and Methods A case control study was conducted among Stage 2 CKD patients (n = 45), aged 30–60 years, attending Saveetha Medical College and Hospital. Patients with type 2 diabetes mellitus, obesity, or hypertension were included. Individuals with acute inflammatory conditions or end-stage renal disease were excluded. Serum renal and lipid parameters were analyzed using an automated dry chemistry analyzer, while PON1 levels were estimated by sandwich ELISA. Statistical analysis was performed using SPSS version 15.0.

Results

All CKD patients (100%) demonstrated significantly reduced serum PON1 levels (

Zitieren

APA

Keerthika, E., Kedari, G., & Ananthi, N. (2026). Serum Paraoxonase-1: A Key Modulator of Lipid Abnormalities and Atherosclerotic Risk in Early Stage Chronic Kidney Disease. International Journal of Drug Delivery Technology, 16(35s). https://doi.org/10.25258/ijddt.16.35s.77

Vancouver

Keerthika E, Kedari G, Ananthi N. Serum Paraoxonase-1: A Key Modulator of Lipid Abnormalities and Atherosclerotic Risk in Early Stage Chronic Kidney Disease. International Journal of Drug Delivery Technology. 2026;16(35s). doi:10.25258/ijddt.16.35s.77

BibTeX
@article{Keerthika2026,
  author = {Keerthika, E. and Kedari, GSR and Ananthi, N.},
  title = {Serum Paraoxonase-1: A Key Modulator of Lipid Abnormalities and Atherosclerotic Risk in Early Stage Chronic Kidney Disease},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {35s},
  doi = {10.25258/ijddt.16.35s.77}
}
Kostenlos starten →